MedTrace Logo

Effects of BCG on Immune Response

NCT02085590 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-05-13

No results posted yet for this study

Summary

In the present study, we want to investigate whether BCG-vaccination enhances the innate immune response in humans in vivo during (single) human endotoxemia.

In a future experiment we will investigate whether BCG-vaccination can reverse the tolerant state observed upon a second LPS administration.

Our goal is to ultimately translate our results into clinic applications to reverse for example sepsis-induced immunoparalysis.

Conditions

Interventions

BIOLOGICAL

BCG vaccine

BIOLOGICAL

Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Peter Pickkers, Prof. · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-10-31
Completion
2014-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02085590 on ClinicalTrials.gov